Axogen appoints Adrian Tyndall to board; founding director Mark Gold retires Dec 13

Axogen, Inc.

Founding director Dr. Mark Gold resigns effective Dec 13, 2022; no dispute cited.
Dr. Adrian Tyndall appointed to board effective Dec 13; will serve on Quality, Compliance & Portfolio Committee.
Tyndall is Exec VP for Health Affairs & Dean of Morehouse School of Medicine; former UF College of Medicine interim dean.
Tyndall receives standard director compensation: $10k quarterly cash retainer, $1.25k committee retainer, $275k initial option grant vesting over 3 years.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Gold

Director

AXGN · Axogen, Inc.

Effective: 2022-12-13
Successor: Joseph Adrian Tyndall
Filed: October 31, 2022, 7:59 PM ET

On October 24, 2022, Mark Gold, M.D. notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Quality, Compliance and Portfolio Management Committee, effective as of 3:00 PM EST on Tuesday, December 13, 2022.

Appointed

Joseph Adrian Tyndall

Director

AXGN · Axogen, Inc.

Effective: 2022-12-13
Filed: October 31, 2022, 7:59 PM ET

On October 25 2022, the Company's Board appointed Joseph Adrian Tyndall, M. D. as a new director to fill the vacant directorship on the Board, effective December 13, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Gold resigned as Director at Axogen, Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 24, 2022, Mark Gold, M.D. notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Quality, Compliance and Portfolio Management Committee, effective as of 3:00 PM EST on Tuesday, December 13, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Adrian Tyndall was appointed as Director at Axogen, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 25 2022, the Company's Board appointed Joseph Adrian Tyndall, M. D. as a new director to fill the vacant directorship on the Board, effective December 13, 2022.

View on SEC.gov

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-22-000110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.